Breast Fat Grafting vs Breast Implant
아래 사실은 모두 두 엔티티 페이지와 그 출처에서 가져온 것입니다. 양쪽이 함께 기록한 항목을 먼저 대조하고, 나머지는 나란히 보여 줍니다.
의료
Breast Fat GraftingBreast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.갱신 2026년 9월 20일제품
Breast ImplantA breast implant is a silicone-shell medical device filled with silicone gel or saline that is placed to enlarge or reconstruct the breast.갱신 2026년 9월 20일둘의 관계Breast Fat Grafting — 대체 관계 → Breast Implant
공통 항목
양쪽 모두 기록된 항목 1개| 항목 | Breast Fat Grafting | Breast Implant |
|---|---|---|
| US regulatory status | Following FDA guidance issued in November 2017, autologous fat grafts do not require premarket approval; stromal vascular fraction products receive closer review | Saline-filled and silicone gel-filled implants are FDA-approved. For breast enlargement, saline requires age 18 or older and silicone gel requires age 22 or older. For reconstruction, both are approved at any age. |
각각의 사실
둘 중 한쪽에만 기록된 검증된 사실입니다.
Breast Fat Grafting
DefinitionFat is taken by liposuction from other parts of the body and injected to enlarge the breasts
Typical donor sitesUsually the abdomen or flanks, though fat can be taken from almost anywhere (surgeon quoted by ASPS)
Typical size increaseSurgeon quoted by ASPS: ideal candidate wants half a cup to one cup; a larger increase may take two to three procedures
Listed risksCysts, infection, microcalcification, death of fat cells (necrosis), and some transferred fat leaving the breast area
Pre-expansion optionSurgeons may recommend an external tissue expansion system in the weeks before surgery
Pooled volume retention54% (95% CI 48.5–59.5%) across 25 studies, follow-up 3–36 months
Retention by fat preparation methodCentrifugation 51.5% vs sedimentation 38.7% pooled retention
Oncologic safety evidenceMeta-analysis of 15 studies (8,541 participants): no difference in overall survival, disease-free survival or local recurrence between patients who had fat grafting after breast cancer surgery and controls
1987 professional positionASPRS (predecessor of ASPS) condemned autologous fat injection for breast augmentation over concerns about cancer detection
2009 ASPS Fat Graft Task ForceConcluded that the literature then available showed no association between fat grafting and higher rates of malignancy
Relevant FDA guidanceSame Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception
Suitable forPeople wanting a relatively small increase in breast size who have enough donor fat (ASPS)
SessionsMore than one session may be needed because part of the graft is resorbed
Imaging noteFat necrosis, cysts and calcifications can appear on mammograms and must be interpreted by a radiologist
Breast Implant
Expected lifespanNot a lifetime device. The longer implants are in place, the more likely they are to need removal or replacement.
Detecting silent rupture (silicone gel)MRI is the most effective method. Ultrasound is an acceptable alternative for screening patients without symptoms.
US labeling guidanceFinal FDA guidance issued September 2020 (docket FDA-2019-D-4467) on patient labeling content and format, including a boxed warning
FDA first linked implants to ALCL2011
BIA-ALCL medical device reports to FDA1,380 reports (US and non-US), including 64 deaths. Median time to diagnosis was 8 years after implantation.
BIA-ALCL reports by implant surfaceTextured 1,010 (73%); smooth 40 (3%, only one with no known history of textured implants); not specified 330 (24%)
Notable recallIn 2019 the FDA asked Allergan to voluntarily recall its Natrelle BIOCELL textured breast implants
South Korea (MFDS) classificationSilicone gel breast implants (실리콘겔인공유방) are Class 4 devices that must be tracked (추적관리대상). Providers must keep records of the patient, device serial number, implantation date and facility.
South Korea BIA-ALCL safety measuresMFDS measures announced 2019-08-28: identify patients with Allergan textured implants, separately register suspected BIA-ALCL cases, and advise annual check-ups starting one year after implantation
Device typeSilicone shell filled with silicone gel or saline; regulated medical device
Known risksRupture, capsular contracture, need for imaging adaptations, possible replacement